Zacks Small Cap Research on MSN

MTVA: Phase 1 part 3 16-week titration study of DA-1726 to initiate in April 2026

By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Phase 1 Part 3 Trial of DA-1726 to ...

MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the first patient has been dosed in Part 3 of its Phase 1 ...
Monthly Prescribing Reference

Study Shows Modified Donanemab Titration Regimen Cuts Risk of ARIA-E

Modified titration was associated with a 41% lower relative risk of ARIA-E than the standard dosing regimen. Topline results were announced from a phase 3b trial evaluating various dosing regimens of ...
Yahoo Finance

MTVA: Phase 1 Part 3 16-Week Titration Study of DA-1726 to Initiate in April 2026…

On March 18, 2026, MetaVia, Inc. (NASDAQ: MTVA) announced the approval of the clinical trial plan by the Institutional Review Board (IRB) at Clinical Pharmacology of Miami for the company’s Phase 1 ...